Competitive Technologies' (CTT) Pain Therapy Medical Device to be Used in Independent Clinical Study
More News related to CTT
- Competitive Technologies Selects RF|Binder as Public Relations Agency of Record
- Competitive Technologies Booking Revenue From Worldwide Shipments of Pain Therapy Medical Devices
- Photo Release -- Competitive Technologies' Medical Device Receives Innovation Award
- Competitive Technologies Announces Outlook for Fiscal 2010 and Financial Results for Fiscal 2009
- Competitive Technologies' Pain Therapy Medical Device to Treat Patients at University of Wisconsin-Madison
Competitive Technologies, Inc. (NYSE: CTT) announced that CTT's pain therapy medical device will be used by clinical investigators at the Virginia Commonwealth University Massey Cancer Center (Massey) for a Phase II independent clinical study. The study will examine the ability of CTT's U.S. FDA-cleared device to decrease pain associated with chemotherapy-induced peripheral neuropathy (CIPN).
"We are very proud to be able to offer this breakthrough device for clinical research study at VCU Massey Cancer Center, a National Cancer Institute-designated center that helps lead our nation's cancer research agenda," said John B. Nano, CTT's Chairman, President and CEO.
Related Categories
Corporate NewsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
